if i was bta management, page-5

Biota is in a fantastic position, but there will not be unlimited lani royalties available. Any arrangement that corrects a previously negotiated relenza deal would impact on a GSK lani deal. Since DS is our 50% lani partner, DS could not tolerate that impact. Biota's reputation would be compromised and future negotiations would suffer. The best we can hope for is a high value lani deal, this time negotiated from a stronger position.

Biota's policy is to "add value" to its discoveries. The possibility of US fast tracking already in place obviously fits. This might be one of the reasons why "Peter Cook remains confident that a licensing deal can be transacted by mid year". (refer Bioshares 19 Feb, www.biota.com.au). Waiting another 3 months for that seems OK.